Get the Stockscreener App
39.53
0.93%
-0.37
After Hours:
39.53
Royalty Pharma Plc stock is traded at $39.53, with a volume of 4.75M.
It is down -0.93% in the last 24 hours and up +5.30% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$39.90
Open:
$40.04
24h Volume:
4.75M
Relative Volume:
1.11
Market Cap:
$16.89B
Revenue:
$2.31B
Net Income/Loss:
$1.66B
P/E Ratio:
17.21
EPS:
2.297
Net Cash Flow:
$827.02M
1W Performance:
-0.03%
1M Performance:
+5.30%
6M Performance:
+18.85%
1Y Performance:
+49.56%
1-Day Range:
$39.49
$40.21
1-Week Range:
$39.23
$40.50
52-Week Range:
$24.05
$41.24
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
39.53 | 17.05B | 2.31B | 1.66B | 827.02M | 2.297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.15 | 107.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
742.00 | 78.84B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.93 | 60.05B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
915.36 | 55.10B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.60 | 45.09B | 447.02M | -1.18B | -906.14M | -6.1812 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
How Royalty Pharma plc (RPD) stock correlates with oil marketsWeekly Market Outlook & Weekly High Return Stock Opportunities - Newser
Royalty Pharma PLC $RPRX Shares Purchased by River Road Asset Management LLC - MarketBeat
Why Royalty Pharma plc (RPD) stock could break out in 2025July 2025 Spike Watch & Precise Swing Trade Entry Alerts - Newser
Will Royalty Pharma plc (RPD) stock maintain strong growthQuarterly Earnings Report & Risk Managed Investment Strategies - Newser
Technical Reactions to RPRX Trends in Macro Strategies - news.stocktradersdaily.com
Royalty Pharma PLC $RPRX Shares Sold by Charles Schwab Investment Management Inc. - MarketBeat
Royalty Pharma PLC $RPRX Shares Sold by Elo Mutual Pension Insurance Co - MarketBeat
Patient Capital Management LLC Buys 15,342 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Northwest & Ethical Investments L.P. Takes $1.67 Million Position in Royalty Pharma PLC $RPRX - MarketBeat
Russell Investments Group Ltd. Sells 286,493 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Franklin Resources Inc. Buys 151,248 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Insider Sold Shares Worth $2,682,505, According to a Recent SEC Filing - MarketScreener
Creative Planning Buys 9,718 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma’s Q3 2025 Earnings Call Highlights - MSN
Terrance Coyne Sells 69,582 Shares of Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
Is Royalty Pharma PLC Gaining or Losing Market Support? - Benzinga
Rhenman & Partners Asset Management AB Lowers Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma EVP Coyne sells $2.68 million in shares By Investing.com - Investing.com South Africa
Royalty Pharma EVP Coyne sells $2.68 million in shares - Investing.com
RPRX CFO Terrance P. Coyne reports 10b5-1 share sales - Stock Titan
Swiss National Bank Purchases 50,100 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma to Present at Upcoming Investor Conferences - Enidnews.com
Legal & General Group Plc Has $97.97 Million Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Vestor Capital LLC Sells 399,100 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc : Technically solid - MarketScreener
Handelsbanken Fonder AB Lowers Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Horizon Kinetics Asset Management LLC Boosts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Mediolanum International Funds Ltd Has $2.01 Million Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
DNB Asset Management AS Increases Position in Royalty Pharma PLC $RPRX - MarketBeat
Shareholder TPC RP 2021 LLC Files To Sell 65,832 Of Royalty Pharma PLC [RPRX] - TradingView
Vanguard Group Inc. Trims Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Sierra Summit Advisors LLC Buys Shares of 19,360 Royalty Pharma PLC $RPRX - MarketBeat
CenterBook Partners LP Increases Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Ensign Peak Advisors Inc Raises Stake in Royalty Pharma PLC $RPRX - MarketBeat
Prudential PLC Has $4.68 Million Stake in Royalty Pharma PLC $RPRX - MarketBeat
55,337 Shares in Royalty Pharma PLC $RPRX Bought by Entropy Technologies LP - MarketBeat
Royalty Pharma (NASDAQ:RPRX) EVP George Lloyd Sells 132,426 Shares - MarketBeat
Royalty Pharma PLC (GB00BMVP7Y09.SG) stock price, news, quote and history - Yahoo Finance Australia
Royalty Pharma PLC $RPRX Shares Sold by Brandywine Global Investment Management LLC - MarketBeat
ABN AMRO Bank N.V. Buys New Shares in Royalty Pharma PLC $RPRX - MarketBeat
Can WPIL Limited Deliver Through Market Peaks and TroughsVolume Profile Analysis & Start Investing With Free Smart Watchlists - earlytimes.in
Royalty Pharma Insider Sold Shares Worth $5,192,656, According to a Recent SEC Filing - MarketScreener
[Form 4] Royalty Pharma plc Insider Trading Activity - Stock Titan
Empowered Funds LLC Cuts Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Terrance Coyne Sells 69,594 Shares of Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
TD Cowen Downgrades Royalty Pharma (NASDAQ:RPRX) to Hold - MarketBeat
How Royalty Pharma plc (RPD) stock compares with top peersGold Moves & Short-Term Swing Trade Alerts - newser.com
SG Americas Securities LLC Acquires 15,218 Shares of Royalty Pharma PLC $RPRX - MarketBeat
7,082 Shares in Royalty Pharma PLC $RPRX Bought by Savant Capital LLC - MarketBeat
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
1.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):